Literature DB >> 24963038

Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.

Salil Sharma1, Soban Umar1, Francois Potus1, Andrea Iorga1, Gabriel Wong1, David Meriwether1, Sandra Breuils-Bonnet1, Denise Mai1, Kaveh Navab1, David Ross1, Mohamad Navab1, Steeve Provencher1, Alan M Fogelman1, Sébastien Bonnet1, Srinivasa T Reddy1, Mansoureh Eghbali2.   

Abstract

BACKGROUND: Pulmonary arterial hypertension is a chronic lung disease associated with severe pulmonary vascular changes. A pathogenic role of oxidized lipids such as hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids is well established in vascular disease. Apolipoprotein A-I mimetic peptides, including 4F, have been reported to reduce levels of these oxidized lipids and improve vascular disease. However, the role of oxidized lipids in the progression of pulmonary arterial hypertension and the therapeutic action of 4F in pulmonary arterial hypertension are not well established. METHODS AND
RESULTS: We studied 2 different rodent models of pulmonary hypertension (PH): a monocrotaline rat model and a hypoxia mouse model. Plasma levels of hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids were significantly elevated in PH. 4F treatment reduced these levels and rescued preexisting PH in both models. MicroRNA analysis revealed that microRNA-193-3p (miR193) was significantly downregulated in the lung tissue and serum from both patients with pulmonary arterial hypertension and rodents with PH. In vivo miR193 overexpression in the lungs rescued preexisting PH and resulted in downregulation of lipoxygenases and insulin-like growth factor-1 receptor. 4F restored PH-induced miR193 expression via transcription factor retinoid X receptor α.
CONCLUSIONS: These studies establish the importance of microRNAs as downstream effectors of an apolipoprotein A-I mimetic peptide in the rescue of PH and suggest that treatment with apolipoprotein A-I mimetic peptides or miR193 may have therapeutic value.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  apolipoprotein A-I mimetic peptide 4F; lipoproteins; miR-193, human; microRNAs; pulmonary arterial hypertension

Mesh:

Substances:

Year:  2014        PMID: 24963038      PMCID: PMC4194270          DOI: 10.1161/CIRCULATIONAHA.114.007405

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.

Authors:  Satoshi Imaizumi; Mohamad Navab; Cecilia Morgantini; Christina Charles-Schoeman; Feng Su; Feng Gao; Murray Kwon; Ekambaram Ganapathy; David Meriwether; Robin Farias-Eisner; Alan M Fogelman; Srinivasa T Reddy
Journal:  Circ J       Date:  2011-05-28       Impact factor: 2.993

3.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells.

Authors:  S B Shappell; R A Gupta; S Manning; R Whitehead; W E Boeglin; C Schneider; T Case; J Price; G S Jack; T M Wheeler; R J Matusik; A R Brash; R N Dubois
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

Review 4.  Inflammation and immune regulation by 12/15-lipoxygenases.

Authors:  Hartmut Kühn; Valerie B O'Donnell
Journal:  Prog Lipid Res       Date:  2006-03-31       Impact factor: 16.195

5.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

Review 6.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

7.  L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.

Authors:  Jingsong Ou; Zhijun Ou; Deron W Jones; Sandra Holzhauer; Ossama A Hatoum; Allan W Ackerman; Dorothee W Weihrauch; David D Gutterman; Karen Guice; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

Review 8.  Novel approaches to treat experimental pulmonary arterial hypertension: a review.

Authors:  S Umar; P Steendijk; D L Ypey; D E Atsma; E E van der Wall; M J Schalij; A van der Laarse
Journal:  J Biomed Biotechnol       Date:  2010-03-22

Review 9.  12/15-lipoxygenase during the regulation of inflammation, immunity, and self-tolerance.

Authors:  Stefan Uderhardt; Gerhard Krönke
Journal:  J Mol Med (Berl)       Date:  2012-09-15       Impact factor: 4.599

Review 10.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.

Authors:  J A Berliner; M Navab; A M Fogelman; J S Frank; L L Demer; P A Edwards; A D Watson; A J Lusis
Journal:  Circulation       Date:  1995-05-01       Impact factor: 29.690

View more
  42 in total

Review 1.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

2.  Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cell-Dependent Endothelial Cell Apoptosis.

Authors:  Grégoire Ruffenach; Ellen O'Connor; Mylène Vaillancourt; Jason Hong; Nancy Cao; Shervin Sarji; Shayan Moazeni; Jeremy Papesh; Victor Grijalva; Christine M Cunningham; Le Shu; Arnab Chattopadhyay; Shuchita Tiwari; Olaf Mercier; Frédéric Perros; Soban Umar; Xia Yang; Aldrin V Gomes; Alan M Fogelman; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

Review 3.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

4.  The first annual Drug Discovery and Development Symposium for Pulmonary Hypertension.

Authors:  John H Newman
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

5.  APOL1-miR-193 Axis as a Bifunctional Regulator of the Glomerular Parietal Epithelium: Maintaining Parietal Cell Phenotype versus Promoting Podocyte Differentiation.

Authors:  Joseph Jessee; Jeffrey B Kopp
Journal:  Am J Pathol       Date:  2018-09-08       Impact factor: 4.307

6.  Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.

Authors:  Hyung J Chun; Sébastien Bonnet; Stephen Y Chan
Journal:  Am J Respir Crit Care Med       Date:  2017-01-15       Impact factor: 21.405

Review 7.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

8.  Downregulation of microRNA-193-3p inhibits the progression of intrahepatic cholangiocarcinoma cells by upregulating TGFBR3.

Authors:  Yu-Long Han; Jia-Jun Yin; Jian-Jun Cong
Journal:  Exp Ther Med       Date:  2018-03-14       Impact factor: 2.447

Review 9.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

Review 10.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.